Sumitomo Life Insurance Co. Sells 505 Shares of Regeneron Pharmaceuticals Inc (REGN)

Share on StockTwits

Sumitomo Life Insurance Co. reduced its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 9.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,675 shares of the biopharmaceutical company’s stock after selling 505 shares during the period. Sumitomo Life Insurance Co.’s holdings in Regeneron Pharmaceuticals were worth $1,920,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of REGN. Norges Bank acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $292,457,000. FMR LLC boosted its position in shares of Regeneron Pharmaceuticals by 6.6% during the fourth quarter. FMR LLC now owns 5,347,376 shares of the biopharmaceutical company’s stock worth $1,997,245,000 after buying an additional 330,875 shares during the period. Morgan Stanley boosted its position in shares of Regeneron Pharmaceuticals by 70.6% during the third quarter. Morgan Stanley now owns 464,603 shares of the biopharmaceutical company’s stock worth $187,719,000 after buying an additional 192,236 shares during the period. American Century Companies Inc. boosted its position in shares of Regeneron Pharmaceuticals by 16.6% during the fourth quarter. American Century Companies Inc. now owns 1,003,471 shares of the biopharmaceutical company’s stock worth $374,796,000 after buying an additional 142,779 shares during the period. Finally, Hexavest Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter worth about $37,955,000. 66.97% of the stock is owned by institutional investors.

In other news, major shareholder Sanofi sold 131,115 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $412.17, for a total value of $54,041,669.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 12.42% of the company’s stock.

Shares of NASDAQ REGN opened at $365.42 on Wednesday. Regeneron Pharmaceuticals Inc has a 52 week low of $281.89 and a 52 week high of $442.00. The company has a quick ratio of 3.67, a current ratio of 4.47 and a debt-to-equity ratio of 0.08. The company has a market cap of $40.18 billion, a P/E ratio of 18.46, a P/E/G ratio of 1.46 and a beta of 1.18.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, February 6th. The biopharmaceutical company reported $6.84 EPS for the quarter, beating the consensus estimate of $5.10 by $1.74. Regeneron Pharmaceuticals had a return on equity of 29.77% and a net margin of 36.43%. The firm had revenue of $1.93 billion during the quarter, compared to analysts’ expectations of $1.73 billion. During the same period in the prior year, the firm posted $5.23 earnings per share. The business’s quarterly revenue was up 21.9% compared to the same quarter last year. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals Inc will post 19.92 EPS for the current year.

Several research analysts have recently weighed in on the company. Jefferies Financial Group reduced their price objective on Regeneron Pharmaceuticals from $376.00 to $343.00 and set a “hold” rating for the company in a research report on Wednesday. BidaskClub cut Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Cantor Fitzgerald reissued a “hold” rating and set a $441.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, February 6th. Oppenheimer increased their price target on Regeneron Pharmaceuticals from $440.00 to $480.00 and gave the company an “outperform” rating in a research report on Thursday, February 7th. Finally, BMO Capital Markets increased their price target on Regeneron Pharmaceuticals to $412.00 and gave the company a “market perform” rating in a research report on Thursday, February 7th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $413.94.

TRADEMARK VIOLATION NOTICE: “Sumitomo Life Insurance Co. Sells 505 Shares of Regeneron Pharmaceuticals Inc (REGN)” was published by Fairfield Current and is the property of of Fairfield Current. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.fairfieldcurrent.com/news/2019/04/17/sumitomo-life-insurance-co-sells-505-shares-of-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

See Also: What is a Real Estate Investment Trust (REIT)?

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply